Loader
Close
needleye robiopsy hero

2022 / Italy

Reshaping biopsy and needle-based therapy through AI-powered robotics. AI, machine learning, and robotics to help radiologists and urologists minimizing the diagnostic error and achieve a speedy and effective therapy.

industry-icon-health

HEALTH

SECTOR

Needleye

EQUITY

DAYONE

Problem.

Prostate cancer is the second most common cancer in men.

In Europe, around 1 million prostate biopsies are carried out each year. Biopsy is still affected by diagnostic errors between 30% and 50%. The main sources of error are target detection and needle insertion: both operator dependent!

Solution.

A safe, accurate and repeatable robot-assisted procedure.

Improve the clinical outcome in needle based prostate biopsy procedures by using AI and robotics through target identification and planning, needle position and biopsy execution.

Ask LOREM and IPSUM

Can you tell us how

NEEDLEYE was born?

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Can you tell us how

NEEDLEYE met DayOne?

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

What Top 3 Tips

would you give to

future innovators ?

I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Partners